The companies are working together to help insurers reduce wasteful spending and spur use of medically necessary tests.
Cigna worked with InformedDNA to come up with scenarios under which it would cover whole-exome sequencing, although it still considers whole-genome analysis investigational.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.